Human CNS-Apolipoprotein E Isoform Production and Clearance A.
Specific Aims : Alzheimer's disease (AD) is a common, devastating disease. 5 million Americans are suffering from AD, and it is currently estimated that by 2050 this number will triple. The only major and wellvalidated genetic risk factor for AD is one's Apolipoprotein E (ApoE) genotype. One ApoE4 allele increases the risk of developing AD by 3-fold, while two copies of ApoE4 increase this risk by 12-fold. A reduced risk for AD is associated with the ApoE2 allele. The metabolism and function of ApoE is partially understood in the periphery, however very little is known about ApoE in the central nervous system (CNS). Because ApoE plays such an important role in the CNS, and because its metabolism in the CNS is not well understood, we propose to determine the physiology and possible isoform pathophysiology as it relates to AD. Isoform dependent changes in ApoE metabolism and amount (and subsequently transport of AP) may underiie the increased risk of AD in humans. Hypothesis 1: ApoE4 amount is less in the brain and CSF vs. ApoE3. Hypothesis 2: ApoE4 clearance rate or turn-over rate if faster in the CNS compared to ApoE3.
Specific Aim : Utilizing a recently developed mass spectrometry assay to measure ApoE isoforms independently, we will measure ApoE4 and ApoE3 in the human brain and CSF. In addition, the in vivo metabolism of human ApoE will be measured using stable isotope-labeling and mass spectrometry in 60 cognitively normal or dementia of the Alzheimer's type (DAT) participants with E2, E3 or E4 ApoE alleles. These participants will be recruited from the Washington University ADRC. B. Relevance to Alzheimer's Disease: ApoE is the strongest genetic risk factor for Alzheimer's disease, and is a potential target for disease-modifying therapies. Our data will provide an important link regarding how ApoE4 may be involved in the pathophysiology of Alzheimer's disease, and may lead to improved therapeutics, which target the major genetic risk factor of Alzheimer's disease, ApoE4.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005681-30
Application #
8459492
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
30
Fiscal Year
2013
Total Cost
$176,943
Indirect Cost
$60,310
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Roe, Catherine M; Ances, Beau M; Head, Denise et al. (2018) Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain 141:3233-3248
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297
Ihara, Ryoko; Vincent, Benjamin D; Baxter, Michael R et al. (2018) Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. Ann Neurol 84:741-753
Swarup, Vivek; Hinz, Flora I; Rexach, Jessica E et al. (2018) Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat Med :
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97:1284-1298.e7
Sutphen, Courtney L; McCue, Lena; Herries, Elizabeth M et al. (2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimers Dement 14:869-879
Bussy, Aurélie; Snider, B Joy; Coble, Dean et al. (2018) Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiol Aging 75:42-50
Vardarajan, Badri N; Barral, Sandra; Jaworski, James et al. (2018) Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer's disease. Ann Clin Transl Neurol 5:406-417

Showing the most recent 10 out of 952 publications